MTHFR 677 C>T Polymorphism Reveals Functional Importance for 5-Methyltetrahydrofolate, Not Homocysteine, in Regulation of Vascular Redox State and Endothelial Function in Human Atherosclerosis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background— The role of circulating homocysteine as an atherosclerosis risk factor has recently been questioned. However, 5-methyl-tetrahydrofolate (5-MTHF), the circulating metabolite of folic acid participating in homocysteine metabolism, has direct effects on vascular function. We sought to distinguish the effects of plasma versus vascular tissue 5-MTHF and homocysteine on vascular redox and endothelial nitric oxide bioavailability in human vessels. Methods and Results— We used the methyl tetrahydrofolate reductase ( MTHFR ) gene polymorphism 677C>T as a model of chronic exposure of the vascular wall to varying 5-MTHF levels in 218 patients undergoing coronary artery bypass graft surgery. Vascular superoxide, vascular 5-MTHF, and total homocysteine were determined in saphenous veins and internal mammary arteries obtained during surgery. Nitric oxide bioavailability was evaluated by organ bath studies on saphenous vein rings. MTHFR genotype was a determinant of vascular 5-MTHF (not vascular homocysteine). Both MTHFR genotype and vascular 5-MTHF were associated with vascular nitric oxide bioavailability and superoxide generated by uncoupled endothelial nitric oxide synthase. In contrast, vascular homocysteine was associated only with NADPH-stimulated superoxide. Conclusions— Genetic polymorphism 677 C>T on MTHFR affects vascular 5-MTHF (but not homocysteine) and can be used as a model to distinguish the chronic effects of vascular 5-MTHF from homocysteine on vascular wall. Vascular 5-MTHF, rather than plasma or vascular homocysteine, is a key regulator of endothelial nitric oxide synthase coupling and nitric oxide bioavailability in human vessels, suggesting that plasma homocysteine is an indirect marker of 5-MTHF rather than a primary regulator of endothelial function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Homocysteine and Cardiovascular Disease
Refsum, H., Ueland, P. M., Nygård, O., & Vollset, S. E. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.31 · Cited by 2,180
Self-citationHomocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa060900 · Cited by 1,729
Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction
Bønaa, K. H., Njølstad, I., Ueland, P. M., Schirmer, H., Tverdal, A., Steigen, T., Wang, H., Nordrehaug, J. E., Arnesen, E., & Rasmussen, K. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055227 · Cited by 1,442
Antoniades, C., Shirodaria, C., Warrick, N., Cai, S., de Bono, J., Lee, J., Leeson, P., Neubauer, S., Ratnatunga, C., Pillai, R., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.612325 · Cited by 365
Self-citationHomocysteine-lowering therapy: a role in stroke prevention?
Spence, J. D. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70219-3 · Cited by 220
Skatchkov, M. P., Sperling, D., Hink, U., Mülsch, A., Harrison, D. G., Sindermann, I., Meinertz, T., & Münzel, T. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9942 · Cited by 188
Antoniades, C., Shirodaria, C., Crabtree, M., Rinze, R., Alp, N., Cunnington, C., Diesch, J., Tousoulis, D., Stefanadis, C., Leeson, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.704155 · Cited by 153
Self-citation
Cited by
Reactive oxygen species in cardiovascular disease
Sugamura, K., & Keaney (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.05.004 · Cited by 769
“The methyl tetrahydrofolate reductase gene polymorphism which affected plasma or circulating 5-MTHF exerts a direct effect on vascular BH4 levels, NO bioavailability, and eNOS coupling in human vessels in vivo [112].”
BackgroundThe Molecular and Cellular Effect of Homocysteine Metabolism Imbalance on Human Health
Škovierová, H., Vidomanová, E., Mahmood, S., Sopková, J., Drgová, A., Červeňová, T., Halašová, E., & Lehotský, J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101733 · Cited by 422
Vita, J. A. (2011) · Circulation · doi:10.1161/circulationaha.111.078824 · Cited by 195
Elshorbagy, A. K., Valdivia-Garcia, M., Mattocks, D. A. L., Plummer, J. D., Smith, A. D., Drevon, C. A., Refsum, H., & Perrone, C. E. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m010215 · Cited by 177
Self-citationZwart, S. R., Gibson, C. R., Gregory, J. F., Mader, T. H., Stover, P. J., Zeisel, S. H., & Smith, S. M. (2017) · The FASEB Journal · doi:10.1096/fj.201700294 · Cited by 59
“Conversely, the decreased availability of folate contributes to oxidative stress and decreased bioavailability of NO via a number of mechanisms (19, 39).”
BackgroundInfluential
Metadata
- Authors
- Antoniades, C., Shirodaria, C., Leeson, P., Baarholm, O. A., Van-Assche, T., Cunnington, C., Pillai, R., Ratnatunga, C., Tousoulis, D., Stefanadis, C., Refsum, H., & Channon, K. M.
- Venue
- Circulation
- Published
- 2009-05-12
- Volume
- 119
- Issue
- 18
- Pages
- 2507-2515
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1993561257
- Cited by
- 151
- References
- 7
- FWCI
- 8.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.